Key result
Despite strong guideline recommendations, SGLT2 inhibitors are underutilized in routine care, with only 14.6% of 105,799 eligible US veterans receiving the therapy in 2020.
Answers are grounded in this paper and cite their sources.
This editorial highlights the significant gap between strong guideline recommendations for SGLT2 inhibitors in HFrEF and their low real-world clinical implementation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Pierce et al. (2023) conducted an editorial in Heart failure with reduced ejection fraction (HFrEF) (n=105,799). SGLT2 inhibitors was evaluated on SGLT2 inhibitor utilization (median rate ratio 1.55). Despite strong guideline recommendations, SGLT2 inhibitors are underutilized in routine care, with only 14.6% of 105,799 eligible US veterans receiving the therapy in 2020.
Synapse has enriched 10 related papers. Consider them for comparative context: